Name: Cytek Biosciences, Inc. (CTKB) Financial Statements
Creator: FinSpry

Cytek Biosciences Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Cytek Biosciences, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	200.45	193.02	164.04	127.95	92.84
Cost of Revenue	89.35	83.59	63.06	48.81	41.13
Gross Profit	111.11	109.43	100.97	79.14	51.71
Operating Expenses
Research & Development	39.40	44.15	34.86	24.44	13.69
Selling, General & Administrative	94.83	93.12	67.92	45.55	24.36
Operating Expenses	134.23	137.27	102.78	69.99	38.05
Operating Income	-23.12	-27.85	-1.80	9.16	13.66
Other Income/Expense
Interest Income	10.36	6.41	4.62	0.05	0.11
Interest Expense	0.00	-2.07	2.57	-1.74	-0.33
Other Income/Expense	4.46	-7.77	1.02	-1.53	0.00
Income
Income Before Tax	-5.70	-15.71	1.26	5.94	14.43
Income Tax Expense	0.32	-3.56	-1.22	2.91	-4.98
Net Income	-6.02	-12.15	2.58	3.05	19.41
Net Income - Continuous Operations	-6.02	-12.15	2.48	3.03	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-15.91	-13.14	9.49	10.40	14.26
EBIT	-23.12	-15.71	3.83	9.16	13.66
Depreciation & Amortization	7.21	2.80	1.70	1.24	0.60
Earnings Per Share
Basic EPS	-	-	-	-	-
Diluted EPS	-	-	-	-	-
Basic Shares Outstanding	130.61	135.28	134.51	76.74	29.13
Diluted Shares Outstanding	130.61	135.28	138.56	81.54	32.60